Harvard Bioscience Q2 revenue up 11% to $22.7M; raises FY2026 revenue guidance to 3-5%

HARVARD BIOSCIENCE INC

Q2 2026 revenue $22.7M, up 11% YoY from $20.5M; FX tailwind of ~1% on constant-currency basis
Net loss widened to ($2.9)M from ($2.3)M; adjusted EBITDA up to $1.7M from $1.5M
H1 net loss narrowed to ($6.3)M from ($52.6)M, which included $48.0M Q1 2025 goodwill impairment
Raises FY 2026 revenue guidance to 3%-5% YoY growth; maintains adjusted EBITDA target
Growth driven by telemetry and CMT products (AAA, electroporation) plus China demand; H1 operating cash flow ($0.3)M vs $5.7M

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.